Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. APGE
5. USO
6. GOOGL
7. MU
8. HOOD
9. DFTX
10. RGNX

Go back to Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer

Guardant Health (GH) PT Raised to $40 at Jefferies

August 8, 2024 6:47 AM EDT

Jefferies analyst Tycho Peterson raised the price target on Guardant Health (NASDAQ: GH) to $40.00 (from $32.00) while maintaining a Buy rating.

The analyst comments "After months of scrutiny on Shield, GH's core therapy selection business stole back some of the spotlight, as G360... More